Martin Brunner

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · The Lancet Neurology · 2016 · 298 citations

Vaccination, Alzheimer's Disease, Vaccine Development +9

Impaired target site penetration of β -lactams may account for therapeutic failure in patients with septic shock

Christian Joukhadar, Martin Frossard, Bernhard X. Mayer et al. · Critical Care Medicine · 2001 · 275 citations

Penetration of Moxifloxacin into Peripheral Compartments in Humans

Markus Müller, Heino Staß, Martin Brunner et al. · Antimicrobial Agents and Chemotherapy · 1999 · 152 citations · Full text

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · Alzheimer s Research & Therapy · 2018 · 140 citations · Full text

Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate<i>R</i>‐[¹¹C]verapamil

Oliver Langer, Martin Bauer, Alexander Hammers et al. · Epilepsia · 2007 · 139 citations · Full text